Clinical Behavior and Treatment of Endometrial Cancer
- 2 December 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC
- Vol. 943, 47-74
- https://doi.org/10.1007/978-3-319-43139-0_2
Abstract
Endometrial cancer is the most common gynecologic malignancy diagnosed in women in the developed nations. It affects a disproportionate number of reproductive-aged women. While the overall prognosis is good compared to other cancers affecting women, the pathogenesis and clinical behavior of endometrial cancer are heterogeneous. The risk factors associated with the type I and type II endometrial cancers and their pathogenesis will be discussed, as well as the evaluation and primary treatment of women with endometrial cancer. The chapter will also focus on risk stratification for recurrence after surgery and role of adjuvant treatments. Finally, the treatment of recurrent endometrial cancer will be presented.Keywords
This publication has 100 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathwayGynecologic Oncology, 2012
- Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinomaGynecologic Oncology, 2012
- Risk of endometrial cancer for women diagnosed with HNPCC‐related colorectal carcinomaInternational Journal of Cancer, 2010
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010
- Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysisThe Lancet, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical stagingGynecologic Oncology, 2008
- A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterusGynecologic Oncology, 2007
- Life‐time risk of different cancers in hereditary non‐polyposis colorectal cancer (hnpcc) syndromeInternational Journal of Cancer, 1995